Kristina, Virta Member

Weight loss results that last

Guide members on their own personalized weight loss journey with our responsible GLP-1 access solution

Weight loss medication use and costs are skyrocketing. Virta can help.

GLP-1 use, both on- and off-label, has led to surging Rx costs for payers, and even medication shortages for people who truly need them.

Icon of a syringe

GLP-1s are effective but expensive and still require lifestyle changes

Icon of a body weight scale

Traditional diet and exercise programs are unsuccessful in helping maintain weight loss

Icon of a bag of money

Costs are rising 2-4x for GLP-1 drug class alone

A better way to navigate GLP-1 costs and utilization

Virta offers new options to manage GLP-1 utilization while protecting access for those who need it. We are industry-leading experts in driving sustained weight loss results, with or without drugs.

Virta offers a better way to control GLP-1 costs:
Cancel icon with a syringe inside

An alternative to GLP-1s

Comparable weight loss to GLP-1s without expensive drugs or regular injections

A sustainable GLP-1 offramp

Deprescribe GLP-1s while helping members retain weight loss

Responsible access

Provider-led management of GLP-1s for people who could benefit from weight loss drugs

Comparable weight loss to GLP-1s at a fraction of the cost

Our members lose weight—while reducing dependence on GLP-1s and other medications—and experience long-lasting results at a fraction of the cost of pharmaceutical or surgical treatments.

After 1 year¹


Average Weight Loss

A proven approach for deprescribing GLP-1s

Our first of its kind research study shows sustained weight loss after deprescribing GLP-1s among a real world population.

Following GLP-1 deprescription, patients weight did not significantly increase at 6 or 12 months post deprescription, compared to many well-known drug trials (in red) where patients regain up to two thirds of weight loss after discontinuing the drug.

Line chart comparing the GLP-1 Deprescriptioon Cohort to the GLP-1 Continued Cohort.
McKenzie, A.L., Athinarayanan, S.J. Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study. Diabetes Ther (2024).

Life-changing weight loss that lasts

** These slides will be converted to a slideshow on the live site. **

Dan lost 110 pounds and changed his attitude

“The Ozempic helped, but there is no magic bullet out there. I needed to change my diet. The energy level I have now is amazing, I’m walking 6-8 miles a day. My attitude is way better too. I didn’t care about a lot of things before, but now I do.”

Benefits leader Sheri knows Virta works first hand

“Within the first three months on Virta, all my numbers had come down and I lost 60 pounds! I can play with my grandkids now and get back up again without pain. It is incredible.“

DeShawn is breaking his family history of diabetes

“Since being on Virta, my blood sugars are so much better, and it’s all from just adjusting what I eat. I’ve also lost about 30 pounds, and I never had to go hungry in order to lose them. I actually love what I get to eat.“

Ready to learn more?

Discover how Virta is helping set a new standard in medical care for people living with obesity, type 2 diabetes, and prediabetes.
Let's talk
Citations and Footnotes
  1. Hallberg SJ et al. Diabetes Therapy. 2018;9(2):583-612 and Bhanpuri NH et al. Cardiovasc Diabetol. 2018; 17:56.